BioAtla (BCAB) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

BioAtla Revenue Highlights


00

BioAtla Revenue by Period


BioAtla Revenue by Year

DateRevenueChange
2023-12-31-100.00%
2022-12-31--100.00%
2021-12-31$250.00K-41.72%
2020-12-31$429.00K-91.75%
2019-12-31$5.20M-51.07%
2018-12-31$10.63M-

BioAtla generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

BioAtla Revenue by Quarter

DateRevenueChange
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$1.71M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31--100.00%
2021-12-31$250.00K66.67%
2021-09-30$150.00K-40.00%
2021-06-30$250.00K100.00%
2021-03-31-100.00%
2020-12-31--100.00%
2020-09-30$150.00K-21.05%
2020-06-30$190.00K113.48%
2020-03-31$89.00K-95.96%
2019-12-31$2.20M-

BioAtla generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

BioAtla Revenue Breakdown


BioAtla Revenue Breakdown by Product

Quarterly Revenue by Product

Product/ServiceJun 21
Service$300.00K

BioAtla's latest quarterly revenue breakdown by segment (product or service), as of Jun 21: Service (100.00%).

BioAtla Revenue Breakdown by Country

Quarterly Revenue by Country

CountryJun 21
Service$300.00K

BioAtla's latest quarterly revenue breakdown by geography, as of Jun 21: Service (100.00%).

BioAtla Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
KYMRKymera Therapeutics$78.59M$3.74M
NRIXNurix Therapeutics$76.99M$12.59M
FHTXFoghorn Therapeutics$34.16M$6.89M
ADAGAdagene$18.11M$833.34K
IKNAIkena Oncology$9.16M-
IPSCCentury Therapeutics$2.23M$771.00K
STTKShattuck Labs$1.66M$1.61M
DSGNDesign Therapeutics--
RZLTRezolute--
CCCCC4 Therapeutics--
ANTXAN2 Therapeutics--
GRCLGracell Bio--
BCABBioAtla--
AVTEAerovate Therapeutics--
OLMAOlema Pharmaceuticals--
ERASErasca--
PASGPassage Bio--
ACRVAcrivon Therapeutics--
PMVPPMV Pharmaceuticals--
GLUEMonte Rosa Therapeutics-$4.70M
NAUTNautilus Bio--

BCAB Revenue FAQ


BioAtla's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. BCAB's yearly revenue for 2021 was $250K, representing a decrease of -41.72% compared to 2020.

BioAtla's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). BCAB's quarterly revenue for Q4 2023 was $1.71M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).

BioAtla's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.